Drug intelligence / Profile preview

SYS-055

Development stage: Preclinical
Lead developer: SATO Pharmaceutical

Overview

**SYS-055** is an investigational Sato Pharmaceutical product evaluated for fatigue reduction. Publicly accessible registry records do not disclose its active composition, molecular target, pharmacologic class, dosage form, or mechanism of action. In a completed open-label, single-arm Japanese study in adults, continuous administration for four weeks was associated with reduced fatigue visual analogue scale measures; 11 participants completed the intervention and no adverse events were reported under the study conditions. ([jrct.mhlw.go.jp](https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031220483))

Beyond the preview

Go deeper on SYS-055.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYS-055.

Explore the full profile